Basal Insulin Hold Threshold at Night
Hold basal insulin at night when capillary blood glucose (CBG) is below 70 mg/dL (3.9 mmol/L), though institutional protocols may vary between 60-100 mg/dL depending on individual hypoglycemia risk factors.
Evidence-Based Threshold
The 2025 ADA Standards of Care emphasize that long-acting basal analogs (U-300 glargine, degludec) convey lower nocturnal hypoglycemia risk than older formulations, but do not specify an exact CBG threshold for holding doses 1. This reflects the reality that no universal guideline-mandated cutoff exists, requiring clinical judgment based on available research.
Risk Stratification Approach
High-Risk Patients (Hold at CBG <100 mg/dL):
- History of severe nocturnal hypoglycemia or hypoglycemia unawareness
- Elderly patients or those with cardiovascular disease
- Patients with HbA1c already at goal or below target
- Recent dose increases or insulin switches (particularly when converting from detemir or U-300 glargine, which may require 10-20% dose reduction) 1
Standard-Risk Patients (Hold at CBG <70 mg/dL):
- Stable insulin regimen
- Intact hypoglycemia awareness
- No recent hypoglycemic episodes
Lower-Risk Patients (Hold at CBG <60 mg/dL):
- Pump users with automated insulin delivery systems
- Patients with continuous glucose monitoring and predictive low-glucose suspend features
Key Modifiable Risk Factors for Nocturnal Hypoglycemia
Research demonstrates that nocturnal hypoglycemia risk increases with:
- Lower HbA1c levels (p=0.006) 2
- Medium/high-intensity exercise during the preceding day (p=0.003) 2
- Antecedent daytime hypoglycemia (p=0.001) 2
- Younger age (p<0.001) 2
Notably, bedtime snacks were NOT protective in research studies 2, though patients using advanced diabetes technology (pumps with CGM) were less likely to use bedtime snacks as a prevention strategy 3.
Timing Considerations
Basal insulin-associated hypoglycemia occurs predominantly between midnight and 8 AM (65.6% of episodes in this timeframe) 4. This makes 3 AM CBG monitoring particularly important for patients on basal insulin regimens, especially when bedtime glucose is trending lower.
Critical Safety Data
A 2014 study demonstrated that 2-hour suspension of basal insulin overnight is safe even when blood glucose is elevated at suspension, with no clinically significant ketonemia (morning β-hydroxybutyrate 0.13 vs 0.09 mmol/L, p=0.053) 5. This provides reassurance that holding a single nighttime dose for hypoglycemia prevention carries minimal ketoacidosis risk.
Common Pitfalls to Avoid
Overbasalization: High bedtime-to-morning glucose differential (≥50 mg/dL) suggests excessive basal insulin masking insufficient mealtime coverage 1. In these cases, reducing basal insulin rather than holding individual doses may be more appropriate.
Failure to adjust after insulin switches: When converting between basal insulins, particularly from U-300 glargine or detemir, initial dose reduction of 10-20% is typically needed 1.
Ignoring exercise history: Medium-to-high intensity exercise significantly increases nocturnal hypoglycemia risk and should lower your threshold for holding insulin 2.
For patients with CGM, utilize predictive low-glucose suspend features rather than relying solely on single CBG measurements, as these systems safely prevent nocturnal hypoglycemia without increasing ketone levels 5.